OMCL Earnings Date: Feb 4, 2027 (Estimated) — Omnicell, Inc.
NASDAQ · Healthcare · Medical - Healthcare Information Services
Updated
When is OMCL's next earnings date?
Omnicell, Inc. (OMCL) is expected to report Q4 2026 earnings on Thursday, February 4, 2027 at 6:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.30 on revenue of $310.5M.
How did OMCL do in its last earnings report?
In its most recent report on Oct 29, 2026 (Q3 2026), Omnicell, Inc. posted EPS of $0.58 versus the $0.42 estimate, a beat of 38.9%. Revenue was $307.9M against a $304.4M estimate. The stock's 1-day post-earnings move was +2.6%.
How much does OMCL stock move after earnings?
OMCL beat EPS estimates in 7 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 11.9% (up or down) in the day after earnings.
About Omnicell, Inc.
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services. In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.
🤖 AI Earnings Analysis
Omnicell’s Q3 beat was modestly positive: EPS of $0.58 topped estimates by $0.16, but revenue slipped 1% year over year to $308M. Healthcare automation growth remains unproven; full-year EPS guidance of $2.15–$2.30 offers limited reassurance.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-29 | Q3 2026 | 0.42 | 0.58 | +38.92% | $307.9M | ✅ Beat | +2.59% | — | — |
| 2026-07-30 | Q2 2026 | 0.44 | 0.94 | +113.64% | $312.2M | ✅ Beat | -10.36% | -10.22% | -19.30% |
| 2026-04-28 | Q1 2026 | 0.29 | 0.55 | +89.66% | $309.9M | ✅ Beat | +20.94% | +15.44% | +14.59% |
| 2026-02-05 | Q4 2025 | 0.41 | 0.40 | -2.44% | $314.0M | ❌ Miss | -16.30% | -19.00% | -11.54% |
| 2025-10-30 | Q3 2025 | 0.28 | 0.51 | +82.14% | $310.6M | ✅ Beat | +13.56% | +20.87% | +23.47% |
| 2025-07-31 | Q2 2025 | 0.21 | 0.45 | +114.29% | $290.6M | ✅ Beat | +4.41% | +4.68% | +12.05% |
| 2025-05-06 | Q1 2025 | 0.20 | 0.26 | +30.00% | $269.7M | ✅ Beat | -15.84% | -9.94% | +2.62% |
| 2025-02-06 | Q4 2024 | 0.58 | 0.60 | +3.45% | $306.9M | ✅ Beat | -11.15% | -8.77% | -16.65% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $312.2M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Connected Devices, Software Licenses, And Other | 47.8% | $149.2M | +7.7% | $157.9M | $120.1M | $138.6M | $152.6M |
| Hardware And Software | 22.0% | $68.6M | +7.8% | — | $63.1M | $63.6M | $65.9M |
| Technical Services | 22.0% | $68.6M | +7.5% | $60.8M | $61.4M | $63.8M | $67.3M |
| Consumables | 8.3% | $25.8M | +5.2% | $24.4M | $25.1M | $24.6M | $24.9M |
By region
Q2 FY26 · $312.2M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 90.0% | $281.0M | +6.7% | $280.7M | $249.3M | $263.4M | $278.2M |
| Non-US | 10.0% | $31.2M | +15.0% | $26.2M | $20.4M | $27.1M | $32.4M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.